利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.024 秒)

    METHOD USING A TRANSCRIPTOMIC SCORE FOR ASSESSING THE CLINICAL OUTCOME OF A PATIENT IN A CLINICAL SETTING, AND MEANS FOR ITS IMPLEMENTATION
    15.
    发明公开
    METHOD USING A TRANSCRIPTOMIC SCORE FOR ASSESSING THE CLINICAL OUTCOME OF A PATIENT IN A CLINICAL SETTING, AND MEANS FOR ITS IMPLEMENTATION 审中-公开

    公开(公告)号：EP4414456A1

    公开(公告)日：2024-08-14

    申请号：EP23305190.3

    申请日：2023-02-13

    申请人： BIOMÉRIEUX ,  Hospices Civils de Lyon ,  UNIVERSITE CLAUDE BERNARD - LYON 1

    发明人： LLITJOS, Jean-François ,  MONNERET, Guillaume

    IPC分类号： C12Q1/12 ,  C12Q1/689

    CPC分类号： C12Q1/689 ,  C12Q2600/15820130101 ,  C12Q2600/11820130101 ,  C12Q1/6883

    摘要： The invention relates to a method of determining, from an assayed sample or a population of assayed samples previously drawn from patients, a transcriptomic score (TScore) suitable for assessing a risk of adverse clinical outcome for patients in a clinical setting, said method involving, amongst other steps, the measurement of gene expression values on a patient sample or a population of samples previously obtained from patients for at least two distinct genes selected among a predetermined set of genes, and the determination of a transcriptomic score where the genes are assigned or not assigned a point. The method can be computer-implemented. The genes of the predetermined set of genes can be at least two genes selected among: ADGRE3, ARL14EP, BPGM, C3AR1, CCNB1IP1, CD177, CD274, CD3D, CD74, CIITA, CTLA4, CX3CR1, GNLY, IFNgamma, IL10, IL1R2, IL1RN, IL7R, IP10/CXCL10, MDC1, OAS2, S100A9, TAP2, TDRD9, TNF and ZAP70. The method can be implemented on assayed biological sample(s) drawn from patient(s) which have been admitted in a reanimation unit, an intensive or continuing care unit. The invention also relates to a method to classify a sample previously drawn from a patient, in a group reflecting a risk of adverse clinical outcome in a clinical setting, or to identify a patient at risk of adverse clinical outcome in a clinical setting, as well as an in vitro or ex vivo method of screening whether a drug has the capacity to alleviate an adverse clinical outcome in a patient. The invention also relates to computer means for implementing the invention, and the use of a kit for carrying out a method of the invention.

    NOUVEAUX DERIVES DE CHALCONE PRESENTANT UNE ACTIVITE ANTI-ALLERGIQUE
    20.
    发明公开
    NOUVEAUX DERIVES DE CHALCONE PRESENTANT UNE ACTIVITE ANTI-ALLERGIQUE 审中-公开
    NEUARTIGE CHALKONDERIVATE MIT ANTIALLERGISCHER WIRKUNG

    公开(公告)号：EP2981521A1

    公开(公告)日：2016-02-10

    申请号：EP14720658.5

    申请日：2014-04-04

    申请人： Université Claude Bernard Lyon I ,  Les Hospices Civils de Lyon ,  Centre National de la Recherche Scientifique

    发明人： DUMONTET, Charles ,  BOUMENDJEL, Ahcène ,  MONNERET, Guillaume

    IPC分类号： C07D211/22 ,  A61K31/4418 ,  A61P37/08

    CPC分类号： C07D211/32 ,  C07D211/22

    摘要： The present invention concerns compounds of formula (I); in which; - R
    2 , R4 and R6, identical or different, represent a hydrogen, chlorine, bromine, iodine or fluorine atom, or an -OH or -O-alkyl group comprising 1 to 6 carbon atoms; -R2 and R4, identical or different, represent a hydrogen atom, or an --OH or -Q-alkyl group comprising 1 to 6 carbon atoms; in which R2' and/or R4' represent(s) a methoxy group; - n is equal to 1, 2 or 3; - X = CH2, G, S or N(R7); and - R7 represents a hydrogen atom or an alkyl group comprising 1 to 6 carbon atoms; and the pharmaceutically acceptable hydrates, solvates and salts thereof.

    摘要翻译： 本发明涉及式（I）化合物：其中：R 2，R 4和R 6相同或不同，代表氢，氯溴，碘或氟原子，或基团-OH或-O-烷基，包括 1至6个碳原子; R 2'和R 4'相同或不同，表示氢原子或包含1至6个碳原子的基团-OH或-O-烷基; 其中R2'和/或R4'代表甲氧基; n等于1,2,3; X = CH 2，O，S或N（R 7）; 并且R 7表示氢原子或含有1至6个碳原子的烷基; 以及其药学上可接受的水合物，溶剂化物和盐。